Patent 9067963 was granted and assigned to Lewis and Clark Pharmaceuticals on June, 2015 by the United States Patent and Trademark Office.
The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5′-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.